Abstract
Over the last decade, high-dose chemotherapy (HDC) with autologous stem- cell transplantation has been explored for a variety of solid tumors in adults, particularly breast cancer, ovarian cancer, and nonseminomatous germ- cell tumors. Response of phase II studies are encouraging in most cases, and, in certain settings, seem clearly superior to historical results of conventional-dose chemotherapy. The value of HDC for adult solid tumors is a highly controversial issue, currently being addressed in large randomized phase II trials. This article reviews the results of HDC in different diseases and depicts potential directions of future progress.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 939-968 |
| Number of pages | 30 |
| Journal | Hematology/Oncology Clinics of North America |
| Volume | 13 |
| Issue number | 5 |
| DOIs | |
| State | Published - 1999 |
| Externally published | Yes |
ASJC Scopus subject areas
- Hematology
- Oncology
Fingerprint
Dive into the research topics of 'Autologous stem-cell transplantation for solid tumors in adults'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS